Atrial Fibrillation Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with symptomatic paroxysmal (comes and goes) or persistent atrial fibrillation (irregular heartbeat), confirmed by a doctor's notes and at least two recorded episodes in the past 12 months.
• You have tried at least one heart rhythm medication but it either did not work or you could not tolerate it.
• Your doctors have determined that you are a suitable candidate for catheter ablation (a procedure to correct the irregular heartbeat).
• You are between 18 and 74 years old.
• You are willing and able to give your informed consent to take part.
• You are able and willing to attend all required appointments and tests before, during, and after the procedure.

Who may not be able to join:

• Your atrial fibrillation has been continuous for more than 12 months.
• Your atrial fibrillation is caused by something treatable or non-heart-related, such as a thyroid problem, electrolyte imbalance, or alcohol use.
• You have previously had a catheter or surgical procedure on the left side of your heart to treat atrial fibrillation, or have had certain heart closure procedures.
• You have had heart valve surgery or a procedure, or you have an artificial heart valve.
• You have had a procedure to treat a blocked artery in your neck (carotid stenting or endarterectomy).
• You have had any heart procedure or heart stenting within the past 90 days.
• You have had heart bypass surgery (CABG) within the past 6 months.
• You are expected to need a heart transplant or other heart surgery within 12 months of the ablation procedure.
• You have an implanted heart defibrillator device.
• You have had a stroke or mini-stroke (TIA) within the past 6 months.
• A blood clot has been found in the upper left chamber of your heart.
• You have a history of abnormal blood clotting or bleeding problems.
• You have a condition that prevents you from safely taking blood-thinning medication long-term.
• You have had a heart attack within the past 3 months.
• Your Body Mass Index (BMI) is over 40 (confirm with trial site if unsure how to calculate this).
• The upper left chamber of your heart is larger than a certain size, depending on your type of atrial fibrillation (confirm with trial site).
• You have been diagnosed with a benign heart tumour called an atrial myxoma.
• Your heart's pumping strength (ejection fraction) is below 40%.
• You have uncontrolled heart failure or severe heart failure symptoms (classified as NYHA Class III or IV).
• You have rheumatic heart disease.
• You have a condition called hypertrophic cardiomyopathy (thickened heart muscle).
• You have unstable angina (chest pain that is not well controlled).
• You have moderate to severe narrowing of the mitral heart valve.
• You have a severely leaky mitral heart valve, based on specific measurements.
• You have a condition called primary pulmonary hypertension (high blood pressure in the lungs).
• You have significant lung disease or a chronic breathing condition.
• Your kidneys are failing and you require dialysis.
• You have an active infection, serious acute illness, or sepsis.
• You have a significant birth defect or medical condition that, in the opinion of the research team, would prevent you from safely participating (confirm with trial site).
• You are currently pregnant, breastfeeding, or are of childbearing age and not using a reliable form of contraception or abstinence.
• You are currently taking part in, or plan to join, another clinical trial during this study, unless the trial sponsor agrees.
• You have a blood clot, tumour, or other problem in your blood vessels that would make the procedure unsafe.
• You have a known dependency on drugs or alcohol.
• Your life expectancy is less than 12 months.
• You are considered a vulnerable person as defined by the research team (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.